Treatment Updates
  • Featured content
    This program includes an interactive video module featuring case studies of real-life patients, introduced by patient narratives and featuring multidisciplinary faculty roundtables and supporting didactic content, with interactive polling questions.
  • Featured content
    Tailored for primary care clinicians, this program explores best practices on screening appropriate patients for HCV, evaluating HCV-infected patients, counseling patients on treatment, and understanding when to refer patients to a specialist.
  • Featured content
    Jordan J. Feld, MD, MPH, illustrates the key data on optimal management of fibrosis and cirrhosis in HBV, including the effect of therapy on fibrosis/cirrhosis regression and HCC and applying the data to clinical practice.
  • Featured content
    In this program, expert faculty review strategies for eliminating HCV infection, both at the individual level and at the population level. An online video module and a downloadable slideset provide an overview of where the HCV field now stands, from the unprecedented levels of efficacy and simplicity in curing individual patients to the steps required to advance toward the goal of eradicating HCV across communities and ultimately throughout the world.
  • Featured content
    In this program, which includes an on-demand multimedia module combining the slides and audio from a live symposium presented at the 2016 annual meeting of the AASLD in Boston, Massachusetts, gain multidisciplinary expert perspectives on best practices in addressing challenging issues in HCV management.
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Programs

10 of 59 Shown
  • Tailored for primary care clinicians, this program explores best practices on screening appropriate patients for HCV, evaluating HCV-infected patients, counseling patients on treatment, and understanding when to refer patients to a specialist.

    Hepatitis C Update: A Growing Challenge With Evolving Management Solutions

    Tailored for primary care clinicians, this program explores best practices on screening appropriate patients for HCV, evaluating HCV-infected patients, counseling patients on treatment, and understanding when to refer patients to a specialist.
    Date Posted: 2/21/2017
  • Jordan J. Feld, MD, MPH, illustrates the key data on optimal management of fibrosis and cirrhosis in HBV, including the effect of therapy on fibrosis/cirrhosis regression and HCC and applying the data to clinical practice.

    The Impact of HBV Therapy on Fibrosis and Cirrhosis

    Jordan J. Feld, MD, MPH, illustrates the key data on optimal management of fibrosis and cirrhosis in HBV, including the effect of therapy on fibrosis/cirrhosis regression and HCC and applying the data to clinical practice.
    Date Posted: 12/22/2016
  • In this program, expert faculty review strategies for eliminating HCV infection, both at the individual level and at the population level. An online video module and a downloadable slideset provide an overview of where the HCV field now stands, from the unprecedented levels of efficacy and simplicity in curing individual patients to the steps required to advance toward the goal of eradicating HCV across communities and ultimately throughout the world.

    HCV: Continuing Advances From Individual Cure to Disease Elimination

    In this program, expert faculty review strategies for eliminating HCV infection, both at the individual level and at the population level. An online video module and a downloadable slideset provide an overview of where the HCV field now stands, from the unprecedented levels of efficacy and simplicity in curing individual patients to the steps required to advance toward the goal of eradicating HCV across communities and ultimately throughout the world.
    Date Posted: 12/7/2016
  • In this program, which includes an on-demand multimedia module combining the slides and audio from a live symposium presented at the 2016 annual meeting of the AASLD in Boston, Massachusetts, gain multidisciplinary expert perspectives on best practices in addressing challenging issues in HCV management.

    Addressing Practical Challenges in HCV Management

    In this program, which includes an on-demand multimedia module combining the slides and audio from a live symposium presented at the 2016 annual meeting of the AASLD in Boston, Massachusetts, gain multidisciplinary expert perspectives on best practices in addressing challenging issues in HCV management.
    Date Posted: 11/28/2016
  • In this on-demand Webcast and downloadable slidesets, expert faculty review the latest diagnostic resources, emerging and investigational therapies, and strategies for improving the care of patients with NASH.

    NASH: Evaluating Emerging Diagnostic and Treatment Strategies

    In this on-demand Webcast and downloadable slidesets, expert faculty review the latest diagnostic resources, emerging and investigational therapies, and strategies for improving the care of patients with NASH.
    Date Posted: 11/22/2016
  • Gain expert perspective on optimal use of promising new checkpoint inhibitors for patients with hepatocellular carcinoma through 3 downloadable PowerPoint slidesets and an on-demand Webcast from the live symposium presented at the 2016 annual meeting of the AASLD in Boston, Massachusetts.

    Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective

    Gain expert perspective on optimal use of promising new checkpoint inhibitors for patients with hepatocellular carcinoma through 3 downloadable PowerPoint slidesets and an on-demand Webcast from the live symposium presented at the 2016 annual meeting of the AASLD in Boston, Massachusetts.
    Date Posted: 11/11/2016
  • In this comprehensive program, which includes a CME-certified video module, downloadable slides, a live Webinar, and 2 ClinicalThought commentaries, expert faculty review the latest guidelines and provide recommendations for the identification, screening, and management of patients at risk for HBV reactivation.

    Identifying and Managing Patients at Risk for HBV Reactivation

    In this comprehensive program, which includes a CME-certified video module, downloadable slides, a live Webinar, and 2 ClinicalThought commentaries, expert faculty review the latest guidelines and provide recommendations for the identification, screening, and management of patients at risk for HBV reactivation.
    Date Posted: 10/18/2016
  • Online text module with embedded, downloadable slides illustrating key data, recent advances, and expert recommendations for managing patients with incurable HCC.

    Recent Advances in Managing Patients With Advanced Incurable HCC

    Online text module with embedded, downloadable slides illustrating key data, recent advances, and expert recommendations for managing patients with incurable HCC.
    Date Posted: 10/7/2016
  • A CME-certified quiz and downloadable slideset developed by expert Keith Stuart, MD, covering recent key concepts in the care of patients with advanced hepatocellular cancer.

    Managing Patients With Advanced HCC: Recent Advances in Systemic Therapy

    A CME-certified quiz and downloadable slideset developed by expert Keith Stuart, MD, covering recent key concepts in the care of patients with advanced hepatocellular cancer.
    Date Posted: 7/21/2016
  • Join Paul Y. Kwo, MD, in this interactive case challenge that will test your clinical decision making skills for 3 HCV-infected patients: one with treatment-naive genotype 3 and decompensated cirrhosis; one with genotype 1a, compensated cirrhosis, and previous pegIFN + RBV + TVR failure; and one with treatment-naive genotype 1b, Child-Pugh class A cirrhosis, and chronic kidney disease.

    Personalizing All-Oral Therapy for Cirrhotic HCV Patients

    Join Paul Y. Kwo, MD, in this interactive case challenge that will test your clinical decision making skills for 3 HCV-infected patients: one with treatment-naive genotype 3 and decompensated cirrhosis; one with genotype 1a, compensated cirrhosis, and previous pegIFN + RBV + TVR failure; and one with treatment-naive genotype 1b, Child-Pugh class A cirrhosis, and chronic kidney disease.
    Date Posted: 4/7/2016
10 of 59 Shown
Show 10 More
Loading...